SCHEMBL3682437

SCHEMBL3682437

Cc1cc(C)c2c(c1O)C(=O)OC2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUAK1 O60285 1/20 0.58
IGF1R P08069 1/20 0.58
MET P08581 1/20 0.58
PIM1 P11309 1/20 0.58
SRC P12931 1/20 0.58
AXL P30530 1/20 0.58
AKT1 P31749 1/20 0.58
KDR P35968 1/20 0.58
NEK2 P51955 1/20 0.58
PLK1 P53350 1/20 0.58
PTK2 Q05397 1/20 0.58
PKN1 Q16512 1/20 0.58
AURKB Q96GD4 1/20 0.58
NEK6 Q9HC98 1/20 0.58
ALK Q9UM73 1/20 0.58
MAOA P21397 11/20 0.57
IMPDH2 P12268 4/20 0.51
IMPDH1 P20839 2/20 0.43
KDM4E B2RXH2 4/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17280322 0.79 NUAK1 (0.54) NUAK1IGF1RMETPIM1SRC
SCHEMBL16870479 0.74 KDM4E (0.47) NUAK1IGF1RMETPIM1SRC
SCHEMBL12149642 0.73 NUAK1 (0.72) NUAK1IGF1RMETPIM1SRC
SCHEMBL31733872 0.73 MAOA (1.00) MAOAMAOB
SCHEMBL30487600 0.73 MAOA (1.00) MAOAMAOB
SCHEMBL3417433 0.72 MAOA (0.49) NUAK1IGF1RMETPIM1SRC
5,7-Dihydroxy-4-Methylphthalide SCHEMBL3505368 0.70 NUAK1 (0.58) NUAK1IGF1RMETPIM1SRC
SCHEMBL16870295 0.70 MAOA (0.68) MAOAMAOB
SCHEMBL9579461 0.69 MAOA (0.47) MAOAIMPDH2KDM4EGAAMEN1
SCHEMBL27881769 0.69 NUAK1 (0.72) NUAK1IGF1RMETPIM1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100203175-A1 DEGLYCATION OF AGEs BASF BEAUTY CARE SOLUTIONS FRANCE S.A.S. (FR) 2010-08-12 US claimed
CN-101765432-A AGE deglycation BASF BEAUTY CARE SOLUTIONS F 2010-06-30 CN claimed
EP-3342396-B1 EXTERNAL PREPARATION FOR SKIN FOR REDUCING SKIN YELLOWNESS HAYASHIBARA CO (JP) 2023-04-12 EP disclosed
EP-3398585-B1 EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME HAYASHIBARA CO (JP) 2020-02-26 EP disclosed
US-10568827-B2 External dermal agent for reducing yellowish dullness Hayashibara Co., Ltd. (JP) 2020-02-25 US disclosed
US-20190008747-A1 EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME Hayashibara Co., Ltd. (JP) 2019-01-10 US disclosed
EP-3398585-A1 EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME Hayashibara Co., Ltd. (JP) 2018-11-07 EP disclosed
US-10111822-B2 External dermal composition for anti-ageing and method for producing the same Hayashibara Co., Ltd. (JP) 2018-10-30 US disclosed
US-20180243195-A1 External dermal agent for reducing yellowish dullness NAGASE VIITA CO., LTD. (JP) 2018-08-30 US disclosed
EP-2939657-B1 SKIN-EXTERIOR ANTI-AGEING COMPOSITION AND PRODUCTION METHOD THEREFOR HAYASHIBARA CO (JP) 2018-08-08 EP disclosed
EP-3342396-A1 EXTERNAL PREPARATION FOR SKIN FOR REDUCING SKIN YELLOWNESS Hayashibara Co., Ltd. (JP) 2018-07-04 EP disclosed
CN-107920981-A Skin external preparation for reducing dark yellow 株式会社林原 2018-04-17 CN disclosed
US-20150342854-A1 EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME Hayashibara Co., Ltd. (JP) 2015-12-03 US disclosed
EP-2939657-A1 SKIN-EXTERIOR ANTI-AGEING COMPOSITION AND PRODUCTION METHOD THEREFOR Hayashibara Co., Ltd. (JP) 2015-11-04 EP disclosed
CN-103816095-A Deglycation of AGEs BASE BEAUTY CARE SOLUTIONS FRANCE S A S 2014-05-28 CN disclosed
US-20100203175-A1 DEGLYCATION OF AGEs BASF BEAUTY CARE SOLUTIONS FRANCE S.A.S. (FR) 2010-08-12 US disclosed
CN-101765432-A AGE deglycation BASF BEAUTY CARE SOLUTIONS F 2010-06-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180243195-A1 External dermal agent for reducing yellowish dullness FUT5, ENGASE, FUT6 NUAK1 3777/4885IGF1R 2698/4885MET 4189/4885
US-10568827-B2 External dermal agent for reducing yellowish dullness FUT5, ENGASE, FUT6 NUAK1 3777/4885IGF1R 2698/4885MET 4189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.